

Novotech and Deloitte brief biotech companies on benefits of accessing Australia's R&D scheme

10 January 2017; San Francisco, California, United States:

At a private event during this year's JP Morgan conference, Novotech and Deloitte briefed international biotech companies on how to access [Australia's R&D Refund Scheme](#) and the regulatory benefits available when undertaking early stage clinical trials in Australia.

Speaking at the event, Deloitte R&D Tax Incentives Account Director Megan O'Connor spoke on how important it was that biopharma CFOs were aware of the tax refund benefits available *well before* selecting clinical trial sites and explained the processes required in accessing these benefits.

Novotech Associate Director Barry Murphy also presented key findings from the latest Frost & Sullivan white paper, '*Australia: Preferred Destination for Early Phase Clinical Trials*'. The white paper revealed how cost, regulatory speed and flexibility, and quality are the key drivers for biopharma companies selecting Australia for early phase trials. A number of case studies were presented suggesting that cash savings of up to 60% versus the US are available when selecting Australia for clinical trials.

[Click to download a copy of the Frost and Sullivan White Paper 'Australia: Preferred Destination for Early Phase Clinical Trials'](#).

For more information, click [here](#) to contact a Novotech representative.

About Novotech - www.novotech-cro.com

Headquartered in Sydney, Novotech is internationally recognised in the industry as a leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.

Novotech's strong Asia Pacific presence included running clinical trials in all key regional markets including Australia, New Zealand, China, Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia, Thailand and India. Novotech also has worldwide reach through the company's network of strategic partners.



Deloitte R&D Tax Incentives Account Director Megan O'Connor



Novotech Associate Director Barry Murphy